Shamsuddin Virani

Dr. Shamsuddin Virani

Hematology | Oncology
709 Spring Valley Rd, 
Burlington, WI 
On Staff At
Offers Telehealth
709 Spring Valley Rd, 
Burlington, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shamsuddin Virani is a Hematologist and an Oncologist in Burlington, Wisconsin. Dr. Virani is rated as an Experienced provider by MediFind in the treatment of Congenital Generalized Fibromatosis. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Non-Hodgkin Lymphoma.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
West Virginia University, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in WI
Board Certifications
American Board Of Internal Medicine, Hematology
Hospital Affiliations
Aurora Medical Center Kenosha
Aurora Lakeland Medical Center
Aurora St Lukes Medical Center
Aurora Memorial Hospital Burlington
Aurora Medical Center - Summit
Languages Spoken
English
Hindi
Urdu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Vince Lombardi Cancer Clinic
709 Spring Valley Rd, Burlington, WI 53105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 17, 2025
Intervention Type: Other, Drug
Study Drug: Naloxegol
Study Phase: Phase 2
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Biological
Study Drugs: Cabozantinib, Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
View 6 Less Clinical Trials

6 Total Publications

ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2024
Similar Doctors
Distinguished in Congenital Generalized Fibromatosis
Dr. John Charlson
Hematology Oncology | Oncology
Distinguished in Congenital Generalized Fibromatosis
Dr. John Charlson
Hematology Oncology | Oncology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
 (29.9 miles away)
414-805-3666
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Charlson is a Hematologist Oncology specialist and an Oncologist in Milwaukee, Wisconsin. Dr. Charlson is rated as an Elite provider by MediFind in the treatment of Congenital Generalized Fibromatosis. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Undifferentiated Pleomorphic Sarcoma.

Experienced in Congenital Generalized Fibromatosis
Dr. Kevin P. Barton
Hematology Oncology | Hematology | Oncology
Experienced in Congenital Generalized Fibromatosis
Dr. Kevin P. Barton
Hematology Oncology | Hematology | Oncology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (60.7 miles away)
708-216-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kevin Barton is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Barton is rated as a Distinguished provider by MediFind in the treatment of Congenital Generalized Fibromatosis. His top areas of expertise are Beta Thalassemia, Shwartzman Phenomenon, Non-Hodgkin Lymphoma, Aplastic Anemia, and Bone Marrow Aspiration. Dr. Barton is currently accepting new patients.

Experienced in Congenital Generalized Fibromatosis
Dr. Ranveer K. Nand
Hematology Oncology | Hematology | Oncology
Experienced in Congenital Generalized Fibromatosis
Dr. Ranveer K. Nand
Hematology Oncology | Hematology | Oncology

Columbia St Marys Hospital Milwaukee Inc

13111 N Port Washington Rd, 
Mequon, WI 
 (45.2 miles away)
262-243-7300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ranveer Nand is a Hematologist Oncology specialist and a Hematologist in Mequon, Wisconsin. Dr. Nand is rated as a Distinguished provider by MediFind in the treatment of Congenital Generalized Fibromatosis. His top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Breast Cancer, and Angiosarcoma. Dr. Nand is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Virani's expertise for a condition
ConditionClose
    View All 19 Distinguished Conditions
    View All 37 Advanced Conditions
    View All 99 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile